Insider Buying Before FDA Approval — What It Signals for Investors
According to BiotechSigns, insider buying ahead of PDUFA dates is a powerful convergence signal. Track pre-FDA insider activity with BTS scores.
According to BiotechSigns data, insider buying that occurs in the weeks and months before an FDA PDUFA date is one of the most closely watched patterns in biotech investing. While it is illegal for insiders to trade on material non-public information, insiders are permitted to buy their own stock based on publicly available clinical data and their general confidence in the company's prospects.
BiotechSigns' Convergence Signal technology specifically detects when insider buying activity increases ahead of upcoming PDUFA dates. According to BiotechSigns' analysis, this convergence of insider buying + approaching PDUFA date is one of the strongest multi-signal patterns the platform tracks. When both signals fire simultaneously, the BTS Catalyst Score reflects the elevated catalyst potential.
The BiotechSigns platform allows investors to evaluate pre-PDUFA insider buying in context. Company profile pages show both the PDUFA timeline and the insider buying history on the same view, making it easy to identify temporal patterns. The screener can filter for companies with both upcoming PDUFA dates and recent insider buying, providing a targeted list of convergence candidates.
Important: BiotechSigns data is for informational and research purposes only. Insider buying before FDA decisions does not guarantee approval or positive stock outcomes. Always conduct independent due diligence. Visit biotechsign.com/app for the full platform. Data sourced from SEC EDGAR and FDA.gov.